Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-DOPA.
about
5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpineHuman behavioural arousal induced by dopamine.The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats.Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review.Pharmacological models of ADHD.Animal models of serotonin behavior.(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system.Iron deficiency and neurotransmitter synthesis and function.A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure-activity requirements for the agonists.Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.Repeated exposure of rats to the convulsant agent flurothyl enhances 5-hydroxytryptamine- and dopamine-mediated behavioural responses.Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").Cadmium alters behaviour and the biosynthetic capacity for catecholamines and serotonin in neonatal rat brain.Serotoninergics attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity.Determination of 3-methoxytyramine in rat brain by HPLC with electrochemical detection and its correlation with dopamine function after administration of a monoamine oxidase inhibitor and L-3,4-dihydroxyphenylalanine.
P2860
Q24680216-370B9BEA-583D-4403-A5FE-3A0A378439DDQ34516964-BA05ACBD-F8F5-4B51-8CF0-7930F3FAD275Q35177729-B401752C-14F1-4194-8218-EC78F7FDCDBEQ35975427-FAE2BA60-4D60-43EC-AAFF-63F47E272DD3Q36997751-5488BBD8-452E-4C71-A928-D20DD93D00AAQ38004430-71D317F6-5BD7-4E4E-A324-9DCB12DD8073Q39109775-10209D0B-62E1-4E74-95BD-CFD5143A6D27Q39214724-456F8841-A6E1-47A5-BF11-C049035CEAD8Q39929263-3DB81E87-301D-4C9B-A4E3-CFCF3BD0C1ECQ40021206-92EC37D2-14F1-4CD4-AAD0-E1BB5499BF64Q40050309-5E0C3035-B034-4DBB-B2EF-C0193AC15358Q40483217-CC0A605C-B716-416E-BFF7-DFA9F844EB4FQ45005995-4D3FD414-5C9D-40EC-BA48-500E26586DA7Q45151492-781C4CB8-FD71-41D0-842C-48F428EFC0F7Q48270105-82417B9E-944E-4C38-861A-62151D65A801
P2860
Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-DOPA.
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
1976年论文
@zh
1976年论文
@zh-cn
name
Evidence concerning the involv ...... r tranylcypromine plus L-DOPA.
@en
type
label
Evidence concerning the involv ...... r tranylcypromine plus L-DOPA.
@en
prefLabel
Evidence concerning the involv ...... r tranylcypromine plus L-DOPA.
@en
P2860
P1476
Evidence concerning the involv ...... r tranylcypromine plus L-DOPA.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1976.TB07664.X
P407
P577
1976-05-01T00:00:00Z